118 related articles for article (PubMed ID: 29079132)
1. SATB1 and bladder cancer: Is there a functional link?
Choudhary D; Clement JM; Choudhary S; Voznesensky O; Pilbeam CC; Woolbright BL; Taylor JA
Urol Oncol; 2018 Mar; 36(3):93.e13-93.e21. PubMed ID: 29079132
[TBL] [Abstract][Full Text] [Related]
2. SATB1 Knockdown Inhibits Proliferation and Invasion and Decreases Chemoradiation Resistance in Nasopharyngeal Carcinoma Cells by Reversing EMT and Suppressing MMP-9.
Zhou D; Ye C; Pan Z; Deng Y
Int J Med Sci; 2021; 18(1):42-52. PubMed ID: 33390772
[No Abstract] [Full Text] [Related]
3. Expression and biological roles of SATB1 in human bladder cancer.
Han B; Luan L; Xu Z; Wu B
Tumour Biol; 2013 Oct; 34(5):2943-9. PubMed ID: 23696028
[TBL] [Abstract][Full Text] [Related]
4. SATB1 overexpression regulates the development and progression in bladder cancer through EMT.
Wan F; Cheng C; Wang Z; Xiao X; Zeng H; Xing S; Chen X; Wang J; Li S; Zhang Y; Xiang W; Zhu Z; Johnson C; Zhu Z
PLoS One; 2015; 10(2):e0117518. PubMed ID: 25706386
[TBL] [Abstract][Full Text] [Related]
5. Analysis of cellular and molecular antitumor effects upon inhibition of SATB1 in glioblastoma cells.
Frömberg A; Rabe M; Oppermann H; Gaunitz F; Aigner A
BMC Cancer; 2017 Jan; 17(1):3. PubMed ID: 28049521
[TBL] [Abstract][Full Text] [Related]
6. Multiple effects of the special AT-rich binding protein 1 (SATB1) in colon carcinoma.
Frömberg A; Rabe M; Aigner A
Int J Cancer; 2014 Dec; 135(11):2537-46. PubMed ID: 24729451
[TBL] [Abstract][Full Text] [Related]
7. SATB1 and SATB2 play opposing roles in c-Myc expression and progression of colorectal cancer.
Mansour MA; Hyodo T; Akter KA; Kokuryo T; Uehara K; Nagino M; Senga T
Oncotarget; 2016 Jan; 7(4):4993-5006. PubMed ID: 26701851
[TBL] [Abstract][Full Text] [Related]
8. SATB1 plays an oncogenic role in esophageal cancer by up-regulation of FN1 and PDGFRB.
Song G; Liu K; Yang X; Mu B; Yang J; He L; Hu X; Li Q; Zhao Y; Cai X; Feng G
Oncotarget; 2017 Mar; 8(11):17771-17784. PubMed ID: 28147311
[TBL] [Abstract][Full Text] [Related]
9. [Expression of special AT-rich sequence-binding protein in bladder urothelial carcinoma and its clinical significance].
Liu CX; Wen Y; Xu K; Zheng SB; Xu YW; Chen BS
Nan Fang Yi Ke Da Xue Xue Bao; 2010 Jun; 30(6):1389-91, 1394. PubMed ID: 20584685
[TBL] [Abstract][Full Text] [Related]
10. The Special AT-rich Sequence Binding Protein 1 (SATB1) and its role in solid tumors.
Frömberg A; Engeland K; Aigner A
Cancer Lett; 2018 Mar; 417():96-111. PubMed ID: 29306014
[TBL] [Abstract][Full Text] [Related]
11. SATB1 as oncogenic driver and potential therapeutic target in head & neck squamous cell carcinoma (HNSCC).
Panchal O; Wichmann G; Grenman R; Eckhardt L; Kunz-Schughart LA; Franke H; Dietz A; Aigner A
Sci Rep; 2020 May; 10(1):8615. PubMed ID: 32451408
[TBL] [Abstract][Full Text] [Related]
12. Histone Demethylase KDM7A Regulates Androgen Receptor Activity, and Its Chemical Inhibitor TC-E 5002 Overcomes Cisplatin-Resistance in Bladder Cancer Cells.
Lee KH; Kim BC; Jeong SH; Jeong CW; Ku JH; Kim HH; Kwak C
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32781788
[TBL] [Abstract][Full Text] [Related]
13. Silencing SATB1 inhibits the malignant phenotype and increases sensitivity of human osteosarcoma U2OS cells to arsenic trioxide.
Zhang H; Su X; Guo L; Zhong L; Li W; Yue Z; Wang X; Mu Y; Li X; Li R; Wang Z
Int J Med Sci; 2014; 11(12):1262-9. PubMed ID: 25317073
[TBL] [Abstract][Full Text] [Related]
14. SATB1 Promotes Pancreatic Cancer Growth and Invasion Depending on MYC Activation.
Chen Z; Li Z; Li W; Zong Y; Zhu Y; Miao Y; Xu Z
Dig Dis Sci; 2015 Nov; 60(11):3304-17. PubMed ID: 26108419
[TBL] [Abstract][Full Text] [Related]
15. Inducing cell proliferation inhibition, apoptosis, and motility reduction by silencing long noncoding ribonucleic acid metastasis-associated lung adenocarcinoma transcript 1 in urothelial carcinoma of the bladder.
Han Y; Liu Y; Nie L; Gui Y; Cai Z
Urology; 2013 Jan; 81(1):209.e1-7. PubMed ID: 23153939
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin induces protective autophagy through activation of BECN1 in human bladder cancer cells.
Lin JF; Lin YC; Tsai TF; Chen HE; Chou KY; Hwang TI
Drug Des Devel Ther; 2017; 11():1517-1533. PubMed ID: 28553083
[TBL] [Abstract][Full Text] [Related]
17. SATB1 is a Novel Molecular Target for Cancer Therapy.
Ding M; Pan J; Guo Z; Liu Q; Yang C; Mao L
Cancer Invest; 2018 Jan; 36(1):28-36. PubMed ID: 29381393
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic regulation of long noncoding RNA UCA1 by SATB1 in breast cancer.
Lee JJ; Kim M; Kim HP
BMB Rep; 2016 Oct; 49(10):578-583. PubMed ID: 27697109
[TBL] [Abstract][Full Text] [Related]
19. Fluvastatin-mediated down-regulation of SATB1 affects aggressive phenotypes of human non-small-cell lung cancer cell line H292.
Xu HY; Xue JX; Gao H; Na FF; Li H; Zhang T; Lu Y
Life Sci; 2019 Apr; 222():212-220. PubMed ID: 30557545
[TBL] [Abstract][Full Text] [Related]
20. VEGF-C inhibition reverses resistance of bladder cancer cells to cisplatin via upregulating maspin.
Zhu H; Yun F; Shi X; Wang D
Mol Med Rep; 2015 Aug; 12(2):3163-9. PubMed ID: 25936422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
